Stockscreener 앱 받기
12.88
1.45%
-0.19
시장 영업 전:
13.08
0.20
+1.55%
전일 마감가:
$13.07
열려 있는:
$13.07
하루 거래량:
5.01M
Relative Volume:
1.64
시가총액:
$1.27B
수익:
$669.43M
순이익/손실:
$-609.36M
주가수익비율:
-2.1094
EPS:
-6.1061
순현금흐름:
$-507.20M
1주 성능:
-9.99%
1개월 성능:
-51.38%
6개월 성능:
-40.97%
1년 성능:
-56.31%
1일 변동 폭
$12.73
$13.22
1주일 범위
$12.73
$14.70
52주 변동 폭
$12.73
$39.89
울트라제닉스 파마슈티컬 Stock (RARE) Company Profile
명칭
Ultragenyx Pharmaceutical Inc
전화
415-483-8800
주소
60 LEVERONI COURT, NOVATO, CA
Compare RARE vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
12.88 | 1.41B | 669.43M | -609.36M | -507.20M | -6.1061 |
VRTX
Vertex Pharmaceuticals Inc
|
513.26 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
774.61 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.69 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.62 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
195.92 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
울트라제닉스 파마슈티컬 Stock (RARE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-24 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-10-20 | 개시 | Wells Fargo | Overweight |
| 2025-07-28 | 재개 | H.C. Wainwright | Buy |
| 2025-05-28 | 개시 | William Blair | Outperform |
| 2024-06-06 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-04-22 | 개시 | RBC Capital Mkts | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-06-14 | 재개 | Credit Suisse | Outperform |
| 2023-06-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-04-26 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-01-18 | 재개 | Canaccord Genuity | Buy |
| 2022-12-30 | 재개 | H.C. Wainwright | Buy |
| 2022-11-03 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-08-01 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-03-16 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-09-30 | 개시 | H.C. Wainwright | Buy |
| 2021-08-19 | 개시 | UBS | Sell |
| 2021-07-15 | 개시 | Guggenheim | Neutral |
| 2021-06-29 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Neutral |
| 2021-05-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-05-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Neutral |
| 2021-03-02 | 재개 | Stifel | Buy |
| 2021-02-12 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-12-07 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2020-11-24 | 재개 | Evercore ISI | In-line |
| 2020-11-12 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2019-08-02 | 재개 | Wedbush | Outperform |
| 2019-03-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | 재개 | Raymond James | Outperform |
| 2019-01-02 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | 업그레이드 | Citigroup | Sell → Neutral |
| 2018-09-10 | 개시 | Morgan Stanley | Equal-Weight |
| 2018-06-21 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2018-05-10 | 개시 | Goldman | Neutral |
| 2018-04-18 | 업그레이드 | SunTrust | Hold → Buy |
| 2018-03-22 | 재개 | Piper Jaffray | Overweight |
| 2018-02-21 | 재확인 | Stifel | Buy |
| 2018-01-22 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2018-01-18 | 개시 | Credit Suisse | Outperform |
| 2017-12-05 | 재확인 | Barclays | Equal Weight |
| 2017-12-04 | 업그레이드 | Jefferies | Hold → Buy |
| 2017-09-14 | 업그레이드 | Wedbush | Neutral → Outperform |
모두보기
울트라제닉스 파마슈티컬 주식(RARE)의 최신 뉴스
Why Did RARE Stock Slump 46% After-Hours? - Stocktwits
Technical Reactions to RARE Trends in Macro Strategies - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Encourages Ultragenyx Pharmaceutical Inc. (RARE) Investors to Inquire about Securities Investigation - ACCESS Newswire
RARE Stock Edges Up On Priority Review For Gene Therapy In Rare Metabolic Disorder - Stocktwits
Squarepoint Ops LLC Sells 106,171 Shares of Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx’s GTX-102 failure erases pipeline sales expectations - spglobal.com
RARE Stock Crashes In Worst Day Ever — ‘Pharma Bro’ Martin Shkreli Calls It ‘Very Cheap,’ Floats BioMarin Buyout - Stocktwits
Ultragenyx SVP Theodore Huizenga sells $2,252 in shares By Investing.com - Investing.com South Africa
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - FinancialContent
Ultragenyx SVP Theodore Huizenga sells $2,252 in shares - Investing.com
Ultragenyx (NASDAQ: RARE) exec sells 161 shares for RSU tax, keeps 69,146 - Stock Titan
$Ultragenyx Pharmaceutical (RARE.US)$ get ready - moomoo.com
Why Ultragenyx Pharmaceutical (RARE) Is Down 40.3% After Angelman Trial Failure And Cost-Cut Plan - Yahoo Finance
Ultragenyx Pharmaceutical Inc. (RARE) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Ultragenyx (RARE) Stock Looks Fully Valued Following Its Phase 3 Setback - Yahoo Finance
Ionis Pharma prices first FDA-approved treatment for Alexander disease at $285,000 per dose - Reuters
RARE Stock Plunges As Ultragenyx Misses Key GTX-102 Trial - StocksToTrade
Ultragenyx Stock Crashes After GTX-102 Failure Despite Genglycos Win - timothysykes.com
Ultragenyx Stock Crashes As GTX-102 Failure Erases Optimism - StocksToTrade
RARE Stock Crashes As Ultragenyx Faces GTX-102 Trial Failure - timothysykes.com
The Goldman Sachs Group Issues Pessimistic Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price - MarketBeat
This week in charts: China deals, stock flatlines and Lilly’s M&A spree - BioPharma Dive
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Gap UpTime to Buy? - MarketBeat
Rx Rundown: Eli Lilly, Ultragenyx, Novartis and more - Medical Marketing and Media
Barclays Issues Pessimistic Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price - MarketBeat
Ultragenyx Pharma Is Maintained at Overweight by Barclays - moomoo.com
Ultragenyx Pharmaceutical (NASDAQ:RARE) Rating Lowered to "Hold" at Royal Bank Of Canada - MarketBeat
Wellington Management Group LLP Reduces Stock Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat
Ultragenyx: A 44% Crash After Trial Failure, Two Weeks After First Gene Therapy Approval - Kavout
Ultragenyx Pharmaceutical (RARE) Reports 61% Cornstarch Reduction In 96 Week Phase 3 Data - simplywall.st
Ultragenyx vows 'significant' cuts after experimental rare-disease drug flunks late-stage clinical trial - The Business Journals
Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Cut to $28.00 by Analysts at Jefferies Financial Group - MarketBeat
Ultragenyx Pharma Cut to Market Perform From Outperform by William Blair - Moomoo
Ultragenyx: Angelman Study Setback Creates More Risk For Rare Disease Specialist - Seeking Alpha
Ultragenyx's Apazunersen Fails Phase III Trial | PharmExec - Pharmaceutical Executive
Ultragenyx Shares Crater After Angelman Syndrome Drug Fails Pivotal Trial - finance.biggo.com
Ultragenyx Trial Failure Revives Debate About How to Treat a Rare Neuro Disorder - MedCity News
Ultragenyx Pharmaceutical Target of Unusually Large Options Trading (NASDAQ:RARE) - MarketBeat
Ultragenyx Weighs Future of Angelman Syndrome ASO After Phase III Trial Failure - GenomeWeb
Citigroup Issues Pessimistic Forecast for Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price - MarketBeat
Is Ultragenyx Stock a Buy After GTX-102 Flop? Analysts Point to Commercial Pipeline - Barron's
QUICK SPARK: Pharma Bro Martin Shkreli Says Ultragenyx Should Be M&A Target - Benzinga
Ultragenyx Pharmaceutical (NASDAQ:RARE) Given New $18.00 Price Target at TD Cowen - MarketBeat
Angelman wings clipped by Ultragenyx phase III bust - BioWorld News
Ultragenyx's Apazunersen Fails Phase 3 Angelman Syndrome Trial - BioPharm International
Ultragenyx mulls fate of rare disease programme on Phase III flop - Clinical Trials Arena
Ultragenyx stock downgraded after trial setback (RARE:NASDAQ) - Seeking Alpha
Why Is Ultragenyx (RARE) Up 6.4% Since Last Earnings Report? - Yahoo Finance
RARE Stock Down 46% as Phase III Angelman Syndrome Study Misses Goals - TradingView
Ultragenyx to weigh ‘significant’ cost cuts as Angelman drug fails key study - BioPharma Dive
Ultragenyx sinks as Phase 3 Angelman trial miss slams a key pipeline bet - Quiver Quantitative
울트라제닉스 파마슈티컬 (RARE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
울트라제닉스 파마슈티컬 주식 (RARE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Parschauer Karah Herdman | EVP and Chief Legal Officer |
Aug 03 '26 |
Sale |
24.92 |
1,900 |
47,348 |
92,562 |
| Horn Howard | Chief Financial Officer |
Aug 03 '26 |
Sale |
24.92 |
4,696 |
117,024 |
96,295 |
0.00%
4.36%
자본화:
|
볼륨(24시간):